

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Mediwelcome Healthcare Management & Technology Inc.

麥迪衛康健康醫療管理科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 2159)

VOLUNTARY ANNOUNCEMENT – CAPITAL INCREASE AGREEMENT

This announcement is made by Mediwelcome Healthcare Management & Technology Inc. (麥迪衛康健康醫療管理科技股份有限公司) (the “**Company**”) on a voluntarily basis.

CAPITAL INCREASE AGREEMENT

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, Mediwelcome Beijing Healthcare Technology Co., Ltd.* (北京麥迪衛康醫療科技有限公司) (“**Mediwelcome**”), a subsidiary of the Company, entered into a capital increase agreement (the “**Capital Increase Agreement**”) on 4 August 2021 in relation to the subscription of new registered capital of Shanghai Bohuikang Biological Technology Co., Ltd.* (上海柏慧康生物科技有限公司) (the “**Target Company**”) at a consideration of RMB10 million in cash (the “**Subscription**”).

Details of the Capital Increase Agreement are set out below:

The Target Company is a limited liability company established in the People’s Republic of China on 5 February 2014 with registered capital of RMB2,297,825.

Prior to entering into the Capital Increase Agreement, the Target Company was held by Mediwelcome as to 9.3382% as at the date of this announcement. In view of the proposal of the Target Company for increasing its registered capital, Mediwelcome intended to make further investment in the Target Company. Other shareholders of the Target Company have agreed to waive the right to take up the new registered capital to be subscribed by Mediwelcome and also consented the Subscription.

Pursuant to the Capital Increase Agreement, Mediwelcome has agreed to subscribe for the new registered capital of RMB287,228 in the Target Company, representing approximately 11.11% of the increase in registered capital, at a consideration of RMB10 million. Out of the investment amount contributed into the Target Company by Mediwelcome, RMB287,228 is allocated as the new registered capital of the Target Company, and the remaining RMB9,712,772 is allocated as capital reserve of the Target Company.

Upon completion of the Subscription, Mediwelcome will hold a total of 19.4117% of equity interest in the Target Company.

GENERAL

The transactions contemplated under the Capital Increase Agreement do not constitute notifiable transactions of the Company for the purpose of Chapter 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By Order of the Board
Mediwelcome Healthcare Management & Technology Inc.
Shi Wei
Chairman and Executive Director

Hong Kong, 4 August, 2021

As at the date of this announcement, the executive Directors are Mr. Shi Wei, Mr. Yang Weimin, Mr. Wang Liang, Mr. He Jiyong, Mr. Wang Wei and Mr. Sui Huijun; the non-executive Directors are Ms. Zhang Yitao and Mr. Liu Xia; and the independent non-executive Directors are Mr. Song Ruilin, Mr. Fei John Xiang, Mr. David Zheng Wang and Mr. Yang Xiaoxi.

* *For identification purpose only*